NEW BRUNSWICK, N.J.,
Jan. 17, 2018 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) issued the following
statement regarding today's Inter Partes Reviews regarding
ZYTIGA® (abiraterone acetate):
"We are disappointed in and strongly disagree with the U.S.
Patent and Trademark Office's (USPTO) decisions relating to
ZYTIGA® as part of the Inter Partes Reviews. We
are evaluating our options with respect to a request for rehearing
and/or appeal to the Court of Appeals for the Federal Circuit. We
believe the '438 patent is valid and will continue to vigorously
defend it."
Inter Partes Review decisions by the USPTO do not result
in termination of a 30-month stay triggered under the Hatch-Waxman
Act by the timely filing of a patent infringement lawsuit against a
generic ANDA applicant.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the
people of Johnson & Johnson. We embrace research and science -
bringing innovative ideas, products and services to advance the
health and well-being of people. Our approximately 134,100
employees at more than 250 Johnson & Johnson operating
companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.
View original content with
multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-issues-statement-on-zytiga-inter-partes-reviews-300584251.html
SOURCE Johnson & Johnson